# EDGAR Filing Document

**Accession Number:** 0001106838
**File Stem:** 0001493152-25-015994
**Filing Date:** 2025-9
**Character Count:** 7497
**Document Hash:** 7f72f216d1e44c5114843d69fde652a3
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-25-015994.hdr.sgml**: 20250929

**ACCESSION NUMBER**: 0001493152-25-015994

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20250926

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**FILED AS OF DATE**: 20250929

**DATE AS OF CHANGE**: 20250929

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Sonnet BioTherapeutics Holdings, Inc.
- **CENTRAL INDEX KEY:** 0001106838
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 522102141
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 0930

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-35570
- **FILM NUMBER:** 251356065

**BUSINESS ADDRESS:**
- **STREET 1:** 100 OVERLOOK CENTER
- **STREET 2:** SUITE 102
- **CITY:** PRINCETON
- **STATE:** NJ
- **ZIP:** 08540
- **BUSINESS PHONE:** 609-375-2227

**MAIL ADDRESS:**
- **STREET 1:** 100 OVERLOOK CENTER
- **STREET 2:** SUITE 102
- **CITY:** PRINCETON
- **STATE:** NJ
- **ZIP:** 08540

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Chanticleer Holdings, Inc.
- **DATE OF NAME CHANGE:** 20050510

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** TULVINE SYSTEMS INC
- **DATE OF NAME CHANGE:** 20000214

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): September 26, 2025

**Sonnet BioTherapeutics Holdings, Inc.**

**(Exact name of registrant as specified in its charter)**

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-35570** | **20-2932652** |
| (State or other jurisdiction<br> of incorporation) | (Commission<br> File Number) | (IRS Employer<br> Identification No.) |

---

---

| | |
|:---|:---|
| **100 Overlook Center, Suite 102**<br> **Princeton, NJ** | **08540** |
| (Address of principal executive offices) | (Zip Code) |

---

Registrant's telephone number, including area code: **(609) 375-2227**

**Not Applicable**

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Common Stock, par value $0.0001 per share | SONN | The Nasdaq Capital Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

---

| | |
|:---|:---|
| **Item 5.07** | **Submission of Matters to a Vote of Security Holders.** |

---

On September 26, 2025, Sonnet BioTherapeutics Holdings, Inc. (the "Company") held an annual meeting of stockholders (the "Annual Meeting"). The matters voted on at the Annual Meeting were the following proposals: (1) to elect five directors to the Company's Board of Directors (the "Board") to hold office for the following year until their successors are elected, (2) to approve, on an advisory basis, the executive compensation of the Company's named executive officers (the "Named Executive Officers") as described in the proxy statement (3) to vote, on an advisory basis, on how frequently the Company should seek approval from its stockholders, on an advisory basis, of the compensation paid to the Named Executive Officers, and (4) to ratify the appointment of KPMG LLP as the Company's independent registered public accounting firm for the year ending September 30, 2025.

At the Annual Meeting, the foregoing stockholder proposals were approved, based upon an aggregate of 6,827,352 shares of Common Stock outstanding as of August 26, 2025, which was the record date for the Annual Meeting. The final voting results were as follows:

1. The
 votes cast with respect to the proposal to elect five directors to the Board to hold office for the following year until their successors
 are elected were as follows:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **For** | **For** | **Withheld** | **Withheld** | **Broker**<br> **Non-Votes** | **Broker**<br> **Non-Votes** |
| Raghu Rao |  | 1220258 |  | 325245 |  | 2152189 |
| Donald Griffith |  | 957147 |  | 588356 |  | 2152189 |
| Nailesh Bhatt |  | 1220922 |  | 324581 |  | 2152189 |
| Albert Dyrness |  | 958237 |  | 587266 |  | 2152189 |
| Lori McNeill |  | 1222090 |  | 323413 |  | 2152189 |

---

2. The
 proposal to approve, on an advisory basis, the executive compensation of the Company's Named Executive Officers as described
 in the proxy statement was approved by a majority of the votes cast at the Annual Meeting, based upon the following votes:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Votes For** | **Votes Against** | **Votes Against** | **Abstentions** | **Abstentions** | **Broker Non-Votes** | **Broker Non-Votes** |
| 1209407 |  | 330412 |  | 5678 |  | 2152195 |

---

3. The
 votes cast will respect to the proposal to determine, on an advisory basis, the preferred frequency the Company should seek approval
 from its stockholders, on an advisory basis, of the compensation paid to the Named Executive Officers were as follows:

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **One Year** | **Two Years** | **Two Years** | **Three Years** | **Three Years** | **Abstentions** | **Abstentions** | **Broker Non-Votes** | **Broker Non-Votes** |
| 1394436 |  | 60801 |  | 88271 |  | 1995 |  | 2152189 |

---

4. The
 proposal to ratify the appointment of KPMG LLP as the Company's independent registered public accounting firm for the year
 ending September 30, 2025 was approved by a majority of the votes cast at the Annual Meeting, based upon the following votes:

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Votes For** | **Votes Against** | **Votes Against** | **Abstentions** | **Abstentions** |
| 3181107 |  | 495000 |  | 21585 |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **Sonnet BioTherapeutics Holdings, Inc.** | **Sonnet BioTherapeutics Holdings, Inc.** |
| September 29, 2025 | By: | */s/ Raghu Rao* |
|  | Name: | Raghu Rao |
|  | Title: | Interim Chief Executive Officer |

---